Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass

被引:10
|
作者
Guo, Jiun-Yu [1 ]
Chen, Hsin-Hung [2 ]
Lee, Wei-Jei [3 ]
Chen, Shu-Chun [4 ]
Lee, Shou-Dong [5 ]
Chen, Chih-Yen [6 ,7 ,8 ,9 ,10 ]
机构
[1] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei 112201, Taiwan
[2] Chang Jung Christian Univ, Dept Nutr & Hlth Sci, Tainan 71101, Taiwan
[3] Min Sheng Gen Hosp, Dept Surg, Taoyuan 330056, Taiwan
[4] Chang Gung Inst Technol, Dept Nursing, Taoyuan 33303, Taiwan
[5] Cheng Hsin Gen Hosp, Dept Internal Med, Div Gastroenterol, Taipei 11220, Taiwan
[6] Taipei Vet Gen Hosp, Dept Med, Div Gastroenterol & Hepatol, Taipei 112201, Taiwan
[7] Natl Yang Ming Chiao Tung Univ, Fac Med, Taipei 11221, Taiwan
[8] Natl Yang Ming Chiao Tung Univ, Coll Med, Inst Emergency & Crit Med, Taipei 11221, Taiwan
[9] Chinese Taipei Soc Study Obes, Taipei 110301, Taiwan
[10] Taiwan Assoc Study Small Intestinal Dis, Taoyuan 333423, Taiwan
关键词
obesity; diabetes mellitus; FGF; 19; 21; total bile acid; non-alcoholic fatty liver disease; gastric bypass; ROUX-EN-Y; BARIATRIC SURGERY; SERUM CONCENTRATIONS; SLEEVE GASTRECTOMY; METABOLIC-RATE; FGF21; MELLITUS; FIBROBLAST-GROWTH-FACTOR-19; EXPRESSION; FGF15/19;
D O I
10.3390/nu14030645
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background: Gastric bypass (GB) is an effective treatment for those who are morbidly obese with coexisting type 2 diabetes mellitus (T2DM) or non-alcoholic fatty liver disease (NAFLD). Fibroblast growth factors (FGFs) are involved in the regulation of energy metabolism. Methods: We investigated the roles of FGF 19, FGF 21, and total bile acid among those with morbidly obese and T2DM undergoing GB. A total of 35 patients were enrolled. Plasma FGF 19, FGF 21, and total bile acid levels were measured before surgery (M0), 3 months (M3), and 12 months (M12) after surgery, while the hepatic steatosis index (HSI) was calculated before and after surgery. Results: Obese patients with T2DM after GB presented with increased serum FGF 19 levels (p = 0.024) and decreased total bile acid (p = 0.01) and FGF 21 levels (p = 0.005). DM complete remitters had a higher FGF 19 level at M3 (p = 0.004) compared with DM non-complete remitters. Fatty liver improvers tended to have lower FGF 21 (p = 0.05) compared with non-improvers at M12. Conclusion: Changes in FGF 19 and FGF 21 play differential roles in DM remission and NAFLD improvement for patients after GB. Early increases in serum FGF 19 levels may predict complete remission of T2DM, while a decline in serum FGF 21 levels may reflect the improvement of NAFLD after GB.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy
    Huang, Hsien-Hao
    Lee, Wei-Jei
    Chen, Shu-Chun
    Chen, Tung-Fang
    Lee, Shou-Dong
    Chen, Chih-Yen
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (06)
  • [2] Fibroblast growth factor 21 in non-alcoholic fatty liver disease
    Tucker, Bradley
    Li, Huating
    Long, Xiaoxue
    Rye, Kerry-Anne
    Ong, Kwok Leung
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 101
  • [3] Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease
    Su, Xin
    Kong, Yi
    Peng, Daoquan
    CLINICA CHIMICA ACTA, 2019, 498 : 30 - 37
  • [4] Efficacy of fibroblast growth factor 21 in non-alcoholic fatty liver disease in guinea pigs
    Klaebel, Julie Hviid
    Lykkesfeldt, Jens
    Tveden-Nyborg, Pernille
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 (03) : 385 - 393
  • [5] Fibroblast Growth Factor 21 as a Marker of Prediabetes in Patients with Non-alcoholic Fatty Liver Disease
    Karamfilova, Vera
    Assyov, Yavor
    Nedeva, Iveta
    Gateva, Antoaneta
    Ivanova, Irena
    Cherkezov, Ivanova
    Mateva, Ludmila
    Kamenov, Zdravko
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2022, 33 (03): : 233 - 239
  • [6] Transcription factor EB inhibits non-alcoholic fatty liver disease through fibroblast growth factor 21
    Gong, Qi
    Zhang, Xie
    Sun, Yixuan
    Shen, Jixiang
    Li, Xiuping
    Xue, Chao
    Liu, Zhihua
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2022, 100 (11): : 1587 - 1597
  • [7] Transcription factor EB inhibits non-alcoholic fatty liver disease through fibroblast growth factor 21
    Qi Gong
    Xie Zhang
    Yixuan Sun
    Jixiang Shen
    Xiuping Li
    Chao Xue
    Zhihua Liu
    Journal of Molecular Medicine, 2022, 100 : 1587 - 1597
  • [8] Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease
    Tucker, Bradley
    McClelland, Robyn L.
    Allison, Matthew A.
    Budoff, Matthew J.
    Wu, Ben J.
    Barter, Philip J.
    Rye, Kerry-Anne
    Ong, Kwok Leung
    ATHEROSCLEROSIS, 2020, 299 : 38 - 44
  • [9] The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy
    Liu, Jia
    Xu, Yuan
    Hu, Yanjin
    Wang, Guang
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2015, 64 (03): : 380 - 390
  • [10] Fibroblast growth factor 21 for non-alcoholic steatohepatitis
    Wong, Vincent W. S.
    Adams, Leon A.
    LANCET, 2018, 392 (10165): : 2658 - 2660